• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Cell-specific aptamers for targeted therapies.用于靶向治疗的细胞特异性适配体。
Methods Mol Biol. 2009;535:59-78. doi: 10.1007/978-1-59745-557-2_5.
2
Aptamers targeting cell surface proteins.靶向细胞表面蛋白的适体。
Biochimie. 2018 Feb;145:63-72. doi: 10.1016/j.biochi.2017.11.019. Epub 2017 Dec 2.
3
Aptamers as targeted therapeutics: current potential and challenges.适配体作为靶向治疗药物:当前的潜力与挑战
Nat Rev Drug Discov. 2017 Mar;16(3):181-202. doi: 10.1038/nrd.2016.199. Epub 2016 Nov 3.
4
Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery.用于小干扰RNA递送的细胞类型特异性抗HIV gp120适配体的研发。
J Vis Exp. 2011 Jun 23(52):2954. doi: 10.3791/2954.
5
Cell-Internalization SELEX of RNA Aptamers as a Starting Point for Prostate Cancer Research.细胞内化 SELEX 筛选 RNA 适体作为前列腺癌研究的起点。
Methods Mol Biol. 2021;2174:245-254. doi: 10.1007/978-1-0716-0759-6_15.
6
Nucleic acid aptamers in cancer medicine.癌症医学中的核酸适配体。
FEBS Lett. 2002 Sep 25;528(1-3):12-6. doi: 10.1016/s0014-5793(02)03275-1.
7
Recent developments in cell-SELEX technology for aptamer selection.细胞 SELEX 技术在适配体筛选中的最新进展。
Biochim Biophys Acta Gen Subj. 2018 Oct;1862(10):2323-2329. doi: 10.1016/j.bbagen.2018.07.029. Epub 2018 Jul 27.
8
Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach.基于细胞 SELEX 的适体在分子医学中的应用:一种化学生物学方法。
Acc Chem Res. 2010 Jan 19;43(1):48-57. doi: 10.1021/ar900101s.
9
Selection of 2'F-modified RNA aptamers against prostate-specific antigen and their evaluation for diagnostic and therapeutic applications.针对前列腺特异性抗原的 2'F 修饰 RNA 适体的筛选及其在诊断和治疗中的评估。
Anal Bioanal Chem. 2013 Nov;405(28):9149-57. doi: 10.1007/s00216-013-7350-y. Epub 2013 Sep 17.
10
Selection of RNA aptamers specific to active prostate-specific antigen.筛选与活性前列腺特异性抗原特异性结合的 RNA 适体。
Biotechnol Lett. 2010 Mar;32(3):379-85. doi: 10.1007/s10529-009-0168-1. Epub 2009 Nov 27.

引用本文的文献

1
Evolution of Cell-Type-Specific RNA Aptamers via Live Cell-Based SELEX.通过基于活细胞的SELEX技术实现细胞类型特异性RNA适配体的进化
Methods Mol Biol. 2023;2666:317-346. doi: 10.1007/978-1-0716-3191-1_22.
2
Optimization of RNA Aptamer SELEX Methods: Improved Aptamer Transcript 3'-End Homogeneity, PAGE Purification Yield, and Target-Bound Aptamer RNA Recovery.RNA 适体 SELEX 方法的优化:提高适体转录本 3'末端同质性、PAGE 纯化产率和靶结合适体 RNA 回收率。
Nucleic Acid Ther. 2022 Feb;32(1):74-80. doi: 10.1089/nat.2021.0060. Epub 2021 Nov 10.
3
Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics.癌症研究与临床诊断中基于DNA适配体的荧光传感
Cancers (Basel). 2017 Dec 20;9(12):174. doi: 10.3390/cancers9120174.
4
Beyond adhesion: emerging roles for integrins in control of the tumor microenvironment.超越黏附作用:整合素在肿瘤微环境调控中的新作用
F1000Res. 2017 Aug 31;6:1612. doi: 10.12688/f1000research.11877.1. eCollection 2017.
5
Development of Phosphorothioate DNA and DNA Thioaptamers.硫代磷酸酯DNA和DNA硫适配体的开发。
Biomedicines. 2017 Jul 13;5(3):41. doi: 10.3390/biomedicines5030041.
6
Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome.使用柔性适配体-阳离子脂质体修饰的gRNA将CRISPR/Cas9靶向递送至前列腺癌
Oncotarget. 2017 Feb 7;8(6):9375-9387. doi: 10.18632/oncotarget.14072.
7
Aptamers as targeted therapeutics: current potential and challenges.适配体作为靶向治疗药物:当前的潜力与挑战
Nat Rev Drug Discov. 2017 Mar;16(3):181-202. doi: 10.1038/nrd.2016.199. Epub 2016 Nov 3.
8
Mechanism of three-component collision to produce ultrastable pRNA three-way junction of Phi29 DNA-packaging motor by kinetic assessment.通过动力学评估研究三组分碰撞产生Phi29 DNA包装马达超稳定pRNA三向接头的机制。
RNA. 2016 Nov;22(11):1710-1718. doi: 10.1261/rna.057646.116. Epub 2016 Sep 26.
9
Specific Delivery of MiRNA for High Efficient Inhibition of Prostate Cancer by RNA Nanotechnology.通过RNA纳米技术实现miRNA的特异性递送以高效抑制前列腺癌
Mol Ther. 2016 Aug;24(7):1267-77. doi: 10.1038/mt.2016.85. Epub 2016 Apr 29.
10
Smooth Muscle Cell-targeted RNA Aptamer Inhibits Neointimal Formation.平滑肌细胞靶向RNA适配体抑制内膜增生。
Mol Ther. 2016 Apr;24(4):779-87. doi: 10.1038/mt.2015.235. Epub 2016 Jan 6.

本文引用的文献

1
Comparison of different strategies to select aptamers against a transmembrane protein target.针对跨膜蛋白靶点选择适配体的不同策略比较。
Oligonucleotides. 2006 Winter;16(4):323-35. doi: 10.1089/oli.2006.16.323.
2
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.利用适配体-小干扰RNA嵌合体实现细胞类型特异性的小干扰RNA递送。
Nat Biotechnol. 2006 Aug;24(8):1005-15. doi: 10.1038/nbt1223. Epub 2006 Jun 25.
3
Aptamer mediated siRNA delivery.适体介导的小干扰RNA递送。
Nucleic Acids Res. 2006 Jun 1;34(10):e73. doi: 10.1093/nar/gkl388.
4
Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 2'-hydroxyl uridines in immune responses.单链小干扰RNA比双链小干扰RNA更具免疫刺激性:2'-羟基尿苷在免疫反应中的核心作用。
Eur J Immunol. 2006 May;36(5):1222-30. doi: 10.1002/eji.200535708.
5
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.用于体内癌症化疗的靶向纳米颗粒-适配体生物共轭物。
Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6315-20. doi: 10.1073/pnas.0601755103. Epub 2006 Apr 10.
6
Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery.用于短发夹RNA递送的肿瘤靶向纳米免疫脂质体复合物
Hum Gene Ther. 2006 Jan;17(1):117-24. doi: 10.1089/hum.2006.17.117.
7
Targeted inhibition of alphavbeta3 integrin with an RNA aptamer impairs endothelial cell growth and survival.用RNA适体靶向抑制αvβ3整合素会损害内皮细胞的生长和存活。
Biochem Biophys Res Commun. 2005 Dec 16;338(2):956-63. doi: 10.1016/j.bbrc.2005.10.043. Epub 2005 Oct 21.
8
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors.通过细胞表面受体介导的小干扰RNA体内抗体递送。
Nat Biotechnol. 2005 Jun;23(6):709-17. doi: 10.1038/nbt1101. Epub 2005 May 22.
9
Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase.来自全细胞指数富集的配体系统进化技术的中和适体可抑制RET受体酪氨酸激酶。
PLoS Biol. 2005 Apr;3(4):e123. doi: 10.1371/journal.pbio.0030123. Epub 2005 Mar 22.
10
Intramers and aptamers: applications in protein-function analyses and potential for drug screening.内体和适配体:在蛋白质功能分析中的应用及药物筛选潜力。
Chembiochem. 2005 Jan;6(1):19-26. doi: 10.1002/cbic.200400299.

用于靶向治疗的细胞特异性适配体。

Cell-specific aptamers for targeted therapies.

作者信息

Cerchia Laura, Giangrande Paloma H, McNamara James O, de Franciscis Vittorio

机构信息

Istituto per l'Endocrinologia e Oncologia Sperimentale G. Salvatore, Naples, Italy.

出版信息

Methods Mol Biol. 2009;535:59-78. doi: 10.1007/978-1-59745-557-2_5.

DOI:10.1007/978-1-59745-557-2_5
PMID:19377980
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4443708/
Abstract

Many signalling proteins involved in diverse functions such as cell growth and differentiation can act as oncogenes and cause cellular transformation. These molecules represent attractive targets for cancer diagnosis or therapy and therefore are subject to intensive investigation. Aptamers are small, highly structured nucleic acid molecules, isolated from combinatorial libraries by a procedure termed SELEX. Aptamers bind to a target molecule by providing a limited number of specific contact points imbedded in a larger, defined three-dimensional structure. Recently, aptamers have been selected against whole living cells, opening a new path which presents three major advantages: (1) direct selection without prior purification of membrane-bound targets, (2) access to membrane proteins in their native conformation similar to the in vivo conditions and (3) identification of (new) targets related to a specific phenotype. The ability to raise aptamers against living cells opens some attractive possibilities for new therapeutic and delivery approaches. In this chapter, the most recent advances in the field will be reviewed together with detailed descriptions of the relevant experimental approaches.

摘要

许多参与细胞生长和分化等多种功能的信号蛋白可作为癌基因,导致细胞转化。这些分子是癌症诊断或治疗的有吸引力的靶点,因此受到深入研究。适体是通过一种称为SELEX的程序从组合文库中分离出来的小的、高度结构化的核酸分子。适体通过提供嵌入更大的、确定的三维结构中的有限数量的特定接触点与靶分子结合。最近,已针对完整活细胞筛选出适体,开辟了一条具有三个主要优点的新途径:(1)无需事先纯化膜结合靶标即可直接筛选,(2)在类似于体内条件的天然构象中获取膜蛋白,以及(3)鉴定与特定表型相关的(新)靶标。针对活细胞产生适体的能力为新的治疗和递送方法开辟了一些有吸引力的可能性。在本章中,将回顾该领域的最新进展,并详细描述相关的实验方法。